SHANGHAI, China – October 10, 2025 – MediumBank (Shanghai MediumBank Biotechnology Co., Ltd.) has been honored with the title of "Top CHO Cell Culture Supplier in Asia-Pacific 2025" by the internationally renowned magazine Life Sciences Review. The award recognizes MediumBank’s outstanding product quality, innovative technological capabilities, and robust quality management systems. In conjunction with this recognition, the magazine has also published an in-depth feature interview with Mr. Wang Yantao, Founder and CEO of MediumBank.
Life Sciences Review, a professional publication in the business and technology sectors, is dedicated to highlighting leading companies in the life sciences field. This accolade not only affirms MediumBank’s technical expertise and service capabilities in CHO cell culture but also acknowledges the company’s sustained innovation and dedication to the upstream bioprocessing sector.
In biopharmaceutical manufacturing, CHO (Chinese Hamster Ovary) cells serve as the "core engine" for producing recombinant proteins, monoclonal antibodies, and other biologics, with cell culture media being a critical determinant of productivity, product quality, and cost efficiency. Since its establishment, MediumBank has focused intently on this pivotal area.
As Mr. Wang emphasized in the interview, "By integrating AI-driven optimization technologies with deep bioprocess expertise, we are setting new standards in CHO cell culture—helping our customers accelerate innovation, ensure quality, and reduce development costs." This philosophy is embedded throughout MediumBank’s R&D and service processes and forms the foundation of this latest achievement.
This honor belongs to every client, partner, and team member who has supported MediumBank. Looking ahead, the company remains committed to its vision of "Making Bioprocessing Simpler and More Efficient," continuing to deepen its expertise in upstream biomanufacturing. MediumBank will strive to provide even higher-quality products and services, supporting the high-quality advancement of the global biopharmaceutical industry.
Click to read the full interview feature:
https://www.lifesciencesreviewapac.com/shanghai-mediumbank-biotechnology
